Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ALX Oncology Holdings Inc

ALXO ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.96

▲ +1.03%

Market Cap $271.02M · Vol 202.48K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$271.02M

Micro Cap

Div Yield

N/A

EPS Growth

+64.16%

YoY

RSI (14)

45.89

Momentum

Beta

0.40

vs Market

52W High

$2.66

26.32% below

52W Low

$0.63

211.11% above

Volume

202.48K

Avg 257.37K

P/B

2.37

Price-to-book

ROE

N/A

Return on equity

Free Float

87.71%

Public shares

Shariah Compliance8 STANDARDS

✗ ALX Oncology Holdings Inc (ALXO) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALXO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.67%

-2.00%

-3.92%

-11.31%

YTD

+73.45%

+199.24%

-59.67%

-97.06%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-101,695,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-98.34% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.37
P/FCF	N/A
EPS Growth	+64.16%
Outstanding Shares	138.28M

Technical Indicators

50-Day SMA	$1.90
200-Day SMA	$1.78
RSI (14)	45.89
Beta	0.40
52-Week High	$2.66
52-Week Low	$0.63

Volume Today	202.48K
Avg Daily Volume (30D)	257.37K
Relative Volume	0.79x
Volatility (10D)	66.44
Volatility (30D)	72.33
Free Float	87.71%

Analyst Consensus

BUY

Current Price $1.96

Mean Target $4.25

52W Low$0.63 52W High$2.66

Current

Target

$0.63 $2.66

Current Analyst target

+116.84% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00VR8SF73

ISINUS00166B1052

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 7, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.